XAGEW — CARMELL THERAPEUTICS CORP
什么是 13F 持仓报告?谁需要申报、何时申报 · 13F 持仓报告看不到什么
最后更新: 2026-11-17 · 来源: SEC EDGAR Form 13F-HR
截至Q3 2026,共 1 家机构在其最新 13F 申报中持有 XAGEW(CARMELL THERAPEUTICS CORP),合计申报市值 $10,对应 2.79K 股。按股数计算较上季度增持 0.0%(+0 股),申报市值环比下降 28.6%。持仓集中度较高:前五大持有人占申报市值的 100.0%,前十大的集中度为 100.0%。
CARMELL THERAPEUTICS CORP(XAGEW)的主要机构持有人包括 PERISCOPE CAPITAL INC.、DeepCurrents Investment Group LLC、HIGHBRIDGE CAPITAL MANAGEMENT LLC,按 13F 申报市值在本页 20 家持有人中排名居前。
本页所有数据均来自美国证监会(SEC)13F 季度申报。13F 申报人需在季度结束后 45 天内披露 10 万美元以上的多头持仓;空头、期权对冲与季度内交易不在其列,因此这些数字反映的是机构持仓的季度快照,而非实时仓位。
机构逐季持仓趋势
| 季度 | 持有机构数 | 股数 | 金额 | 环比净变动 |
|---|---|---|---|---|
| Q3 2026 | 1 | 2.79K | $10 | +0.0% |
| Q2 2026 | 1 | 2.79K | $14 | +0.0% |
| Q1 2026 | 1 | 2.79K | $10 | +0.0% |
| Q4 2025 | 1 | 2.79K | $24 | +0.0% |
| Q3 2025 | 1 | 2.79K | $43 | +0.0% |
| Q2 2025 | 12 | 2.17M | $60.60K | -1.6% |
| Q1 2025 | 12 | 1.83M | $59.55K | -0.1% |
| Q4 2024 | 13 | 1.88M | $101.25K | -2.5% |
表内 8 个季度中,机构持股合计减少 100%(Q4 2024 → Q3 2026)。
更早季度的机构持仓记录(逐季列表): 返回前 25 大机构持仓人
Q2 2026 — 1 家基金
| 基金 | 股数 | 金额 | 组合权重 | 变化 |
|---|---|---|---|---|
| 2.79K | $14 | 0.00% | 持有 |
Q1 2026 — 1 家基金
| 基金 | 股数 | 金额 | 组合权重 | 变化 |
|---|---|---|---|---|
| 2.79K | $10 | 0.00% | 持有 |
Q4 2025 — 1 家基金
| 基金 | 股数 | 金额 | 组合权重 | 变化 |
|---|---|---|---|---|
| 2.79K | $24 | 0.00% | 持有 |
Q3 2025 — 1 家基金
| 基金 | 股数 | 金额 | 组合权重 | 变化 |
|---|---|---|---|---|
| 2.79K | $43 | 0.00% | 持有 |
Q2 2025 — 12 家基金
| 基金 | 股数 | 金额 | 组合权重 | 变化 |
|---|---|---|---|---|
| 371.25K | $11.29K | 0.00% | 持有 | |
| 365.07K | $11.10K | 0.00% | 新进 | |
| 371.25K | $9.95K | 0.00% | 持有 | |
| 342.71K | $7.95K | 0.00% | 持有 | |
| 228.30K | $6.12K | 0.00% | 持有 | |
| 188.54K | $5.73K | 0.00% | 持有 | |
| 188.54K | $5.73K | 0.00% | 持有 | |
| 45.58K | $1.06K | 0.00% | 减持 | |
| 44.01K | $1.02K | 0.00% | 减持 | |
| 19.60K | $525 | 0.00% | 持有 | |
| 2.79K | $85 | 0.00% | 持有 | |
| 1.40K | $42 | 0.00% | 减持 |
新建仓(Q3 2026)
本季度没有基金新建该仓位。
完全清仓(较上季)
本季度没有被追踪基金完全清仓。
基金持仓历史 — 各季度股数(前 20 只基金)
| 基金 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ancora Advisors LLC | 2.79K | 2.79K | 2.79K | 2.79K | 2.79K | 2.79K | 2.79K | 2.79K | 2.79K | 2.79K | 2.79K | 2.79K | 2.79K |
| LINDEN ADVISORS LP | — | — | — | — | — | 371.25K | 371.25K | 371.25K | 371.25K | 371.25K | 371.25K | 371.25K | 371.25K |
| PERISCOPE CAPITAL INC. | — | — | — | — | — | — | — | — | — | — | 195.99K | 240.27K | 242.87K |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | — | — | — | — | — | — | — | — | 213.91K | 213.91K | 181.82K | 181.82K | 181.82K |
| WHITEBOX ADVISORS LLC | — | — | — | — | — | — | — | — | 18.75K | 18.75K | 18.75K | 18.75K | 18.75K |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AM | — | — | — | — | — | 371.25K | 371.25K | 371.25K | 371.25K | — | — | 371.25K | 371.25K |
| Balyasny Asset Management | — | — | — | — | — | 342.71K | 342.71K | 342.71K | 342.71K | 342.71K | 342.71K | 342.71K | 342.71K |
| MILLENNIUM MANAGEMENT LLC | — | — | — | — | — | 188.54K | 188.54K | 188.54K | 188.54K | 188.54K | 190.44K | 234.89K | 237.47K |
| Sculptor Capital LP | — | — | — | — | — | 228.30K | 228.30K | 228.30K | 228.30K | 228.30K | 228.30K | 228.30K | 228.30K |
| DeepCurrents Investment Group LLC | — | — | — | — | — | — | — | — | — | — | — | — | 8.75K |
| AQR Arbitrage LLC | — | — | — | — | — | 45.58K | 61.13K | 74.39K | 79.88K | 81.05K | 85.58K | 96.03K | 96.64K |
| Citadel Advisors | — | — | — | — | — | 44.01K | 45.77K | 46.84K | 75.37K | 76.16K | 98.47K | — | — |
| Walleye Capital LLC | — | — | — | — | — | — | — | 45.35K | 50.95K | 50.95K | 50.95K | 50.95K | 50.95K |
| TORONTO DOMINION BANK | — | — | — | — | — | 365.07K | — | — | — | — | — | — | — |
| Saba Capital Management, L.P. | — | — | — | — | — | 19.60K | 19.60K | 19.60K | 19.60K | 19.60K | 19.60K | 19.60K | 19.60K |
| FLOW TRADERS U.S. LLC | — | — | — | — | — | — | — | — | — | — | — | 20.19K | 20.49K |
| WOLVERINE ASSET MANAGEMENT LLC | — | — | — | — | — | — | — | — | 584 | 4.59K | 9.41K | 10.66K | 6.21K |
| UBS Group AG | — | — | — | — | — | 1.40K | 12.69K | 116 | 8.98K | 131 | — | — | 2.71K |
| Bank of America Corp | — | — | — | — | — | — | 200 | 100 | 100 | 100 | 100 | — | — |
| Millennium Management | — | — | — | — | — | 188.54K | 188.54K | 188.54K | 188.54K | 188.54K | 190.44K | 234.89K | 237.47K |
常见问题
Which funds hold XAGEW?
As of 2026-Q3, 1 institutional funds reported holding XAGEW (CARMELL THERAPEUTICS CORP) in SEC 13F filings, with a combined reported value of $10.
How many shares of XAGEW do institutions own?
13F filers reported 2.79K shares of XAGEW, worth $10 in aggregate at the end of 2026-Q3.
Is institutional ownership of XAGEW rising or falling?
Share counts moved +0.0% versus the prior quarter — accumulation.
Who are the top institutional holders of XAGEW?
The largest 13F holders are PERISCOPE CAPITAL INC., DeepCurrents Investment Group LLC, HIGHBRIDGE CAPITAL MANAGEMENT LLC, OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AM, TORONTO DOMINION BANK; the top 25 are ranked at the top of this page.
Who are the major shareholders of CARMELL THERAPEUTICS CORP?
The major shareholders of CARMELL THERAPEUTICS CORP (XAGEW) by reported 13F value are PERISCOPE CAPITAL INC., DeepCurrents Investment Group LLC, HIGHBRIDGE CAPITAL MANAGEMENT LLC, OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AM, TORONTO DOMINION BANK, among 20 institutional holders.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.